专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明公开

EP2822545A4 TREATMENT FOR HIGH CHOLESTEROL 审中-公开
标题翻译：治疗高胆固醇值
公开(公告)号：EP2822545A4
公开(公告)日：2015-08-12
申请号：EP13758366
申请日：2013-03-08
申请人： FIBROGEN INC
发明人： LIN AL Y , NEFF THOMAS B , YU KIN-HUNG
IPC分类号： A61K31/00
CPC分类号： C07D471/04 , A61K31/437 , A61K31/472 , A61K45/06 , C07D217/26 , A61K2300/00

12. 发明公开

EP1578431A4 FAT REGULATION 审中-公开
标题翻译：油脂控制
公开(公告)号：EP1578431A4
公开(公告)日：2008-04-23
申请号：EP03796688
申请日：2003-12-05
申请人： FIBROGEN INC
发明人： FOURNEY PATRICK D , GUENZLER-PUKALL VOLKMAR , KLAUS STEPHEN J , LIN AL Y , NEFF THOMAS B , SEELEY TODD W
IPC分类号： A61K20060101 , A61K31/70 , A61K45/00 , C12Q1/37
CPC分类号： A61K31/70 , A61K45/06 , A61K2300/00
摘要： The present invention provides methods and compounds for regulating fat metabolism and achieving fat homeostasis in a subject. Methods and compound for regulating body weight, reducing body fat, and inducing weight loss are also provided, as are methods and compounds for treating or preventing obesity and for preventing or treating conditions associated with altered fat metabolism including, e.g., obesity, diabetes, atherosclerosis, etc.

14. 发明专利

ES2414706T3 Métodos para aumentar la eritropoyetina endógena 未知
公开(公告)号：ES2414706T3
公开(公告)日：2013-07-22
申请号：ES02805548
申请日：2002-12-06
申请人： FIBROGEN INC
发明人： KLAUS STEPHEN J , LIN AL Y , NEFF THOMAS B , WANG QINGJIAN , GUENZLER-PUKALL VOLKMAR , AREND MICHAEL P , FLIPPIN LEE A
IPC分类号： A61K31/00 , G01N33/50 , A61K31/17 , A61K31/44 , A61K31/4418 , A61K31/47 , A61K31/472 , A61K31/4738 , A61K31/4745 , A61K31/496 , A61K31/555 , A61K31/63 , A61K33/26 , A61K38/00 , A61K38/17 , A61K38/22 , A61K45/00 , A61K45/06 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/06 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/00 , A61P17/02 , A61P25/00 , A61P25/08 , A61P43/00 , C07K14/47 , C07K14/505 , C12N5/06 , C12N9/99 , C12N15/09 , C12Q1/02 , C12Q1/34 , C12Q1/56 , C12Q1/68 , G01N33/15 , G01N33/74
摘要： El uso de un compuesto de carboxamida heterocíclico seleccionado del grupo que consiste enpiridinocarboxamidas, quinolinacarboxamidas, isoquinolinacarboxamidas, cinolinacarboxamidas, y betacarbolinacarboxamidasque inhiben el factor inducible por hipoxia (HIF) de la actividad de la enzima prolil hidroxilasaen la fabricación de un medicamento para aumentar la eritropoyetina endógena en la prevención, el pre-tratamiento,o el tratamiento de la anemia.

15. 发明专利

AU2009200018C1 Methods of increasing endogenous erythropoietin (EPO) 未知
公开(公告)号：AU2009200018C1
公开(公告)日：2013-02-07
申请号：AU2009200018
申请日：2009-01-02
申请人： FIBROGEN INC
发明人： KLAUS STEPHEN J , LIN AL Y , NEFF THOMAS B , WANG QINGJIAN , GUENZLER-PUKALL VOLKMAR , AREND MICHAEL P , FLIPPIN LEE A , MELEKHOV ALEX
IPC分类号： C07K14/47 , G01N33/50 , A61K31/00 , A61K31/44 , A61K31/4418 , A61K31/47 , A61K31/472 , A61K31/4745 , A61K31/496 , A61K31/555 , A61K31/63 , A61K33/26 , A61K38/00 , A61K38/17 , A61K38/22 , A61K45/00 , A61K45/06 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/06 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/00 , A61P17/02 , A61P25/00 , A61P25/08 , A61P43/00 , C07K14/505 , C12N5/06 , C12N9/99 , C12N15/09 , C12Q1/02 , C12Q1/68 , G01N33/15
摘要： The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.

16. 发明专利

AU2009200018B2 Methods of increasing endogenous erythropoietin (EPO) 未知
公开(公告)号：AU2009200018B2
公开(公告)日：2012-05-24
申请号：AU2009200018
申请日：2009-01-02
申请人： FIBROGEN INC
发明人： FLIPPIN LEE A , LIN AL Y , NEFF THOMAS B , KLAUS STEPHEN J , GUENZLER-PUKALL VOLKMAR , MELEKHOV ALEX , AREND MICHAEL P , WANG QINGJIAN
IPC分类号： G01N33/50 , A61K31/00 , A61K31/44 , A61K31/4418 , A61K31/47 , A61K31/472 , A61K31/4745 , A61K31/496 , A61K31/555 , A61K31/63 , A61K33/26 , A61K38/00 , A61K38/17 , A61K38/22 , A61K45/00 , A61K45/06 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/06 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/00 , A61P17/02 , A61P25/00 , A61P25/08 , A61P43/00 , C07K14/47 , C07K14/505 , C12N5/06 , C12N9/99 , C12N15/09 , C12Q1/02 , C12Q1/68 , G01N33/15
摘要： The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.

17. 发明专利

NO20042804A 未知
公开(公告)号：NO20042804A
公开(公告)日：2004-09-06
申请号：NO20042804
申请日：2004-07-02
申请人： FIBROGEN INC
发明人： FLIPPIN LEE ALLEN , NEFF THOMAS B , KLAUS STEPHEN J , LIN AL Y , WANG QINGJIAN , GUENZLER-PUKALL VOLKMAR , AREND MICHAEL P
IPC分类号： G01N33/50 , A61K31/00 , A61K31/44 , A61K31/4418 , A61K31/47 , A61K31/472 , A61K31/4745 , A61K31/496 , A61K31/555 , A61K31/63 , A61K33/26 , A61K38/00 , A61K38/17 , A61K38/22 , A61K45/00 , A61K45/06 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/06 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/00 , A61P17/02 , A61P25/00 , A61P25/08 , A61P43/00 , C07K14/47 , C07K14/505 , C12N5/06 , C12N9/99 , C12N15/09 , C12Q1/02 , C12Q1/68 , G01N33/15 , A61K31/505
CPC分类号： A61K31/4745 , A61K31/00 , A61K31/17 , A61K31/4375 , A61K31/44 , A61K31/4418 , A61K31/47 , A61K31/472 , A61K31/4738 , A61K31/496 , A61K31/63 , A61K38/1709 , C07K14/4702 , C07K14/505 , G01N33/746
摘要： The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.

18. 发明专利

AU2002357096A1 METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) 未知
公开(公告)号：AU2002357096A1
公开(公告)日：2003-07-09
申请号：AU2002357096
申请日：2002-12-06
申请人： FIBROGEN INC
发明人： FLIPPIN LEE A , MELEKHOV ALEX , KLAUS STEPHEN J , LIN AL Y , NEFF THOMAS B , WANG QINGJIAN , GUENZLER-PUKALL VOLKMAR , AREND MICHAEL P
IPC分类号： G01N33/50 , A61K31/00 , A61K31/44 , A61K31/4418 , A61K31/47 , A61K31/472 , A61K31/4745 , A61K31/496 , A61K31/555 , A61K31/63 , A61K33/26 , A61K38/00 , A61K38/17 , A61K38/22 , A61K45/00 , A61K45/06 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/06 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/00 , A61P17/02 , A61P25/00 , A61P25/08 , A61P43/00 , C07K14/47 , C07K14/505 , C12N5/06 , C12N9/99 , C12N15/09 , C12Q1/02 , C12Q1/68 , G01N33/15
摘要： The present invention relates to methods for treating anemia by increasing endogenous erythropoietin via inhibition of HIF prolyl hydroxylase enzyme activity.

19. 发明专利

ES2686625T3 Métodos para el tratamiento o prevención de la anemia 未知
公开(公告)号：ES2686625T3
公开(公告)日：2018-10-18
申请号：ES10181768
申请日：2002-12-06
申请人： FIBROGEN INC
发明人： KLAUS STEPHEN J , LIN AL Y , NEFF THOMAS B , WANG QINGJIAN , GUENZLER-PUKALL VOLKMAR , AREND MICHAEL P , FLIPPIN LEE A
IPC分类号： A61K38/00 , G01N33/50 , A61K31/00 , A61K31/17 , A61K31/4375 , A61K31/44 , A61K31/4418 , A61K31/47 , A61K31/472 , A61K31/4738 , A61K31/4745 , A61K31/496 , A61K31/555 , A61K31/63 , A61K33/26 , A61K38/17 , A61K38/22 , A61K45/00 , A61K45/06 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/06 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/00 , A61P17/02 , A61P25/00 , A61P25/08 , A61P43/00 , C07K14/47 , C07K14/505 , C12N5/06 , C12N9/99 , C12N15/09 , C12Q1/02 , C12Q1/34 , C12Q1/56 , C12Q1/68 , G01N33/15 , G01N33/74
摘要： Un compuesto para su uso en el tratamiento o prevención de la anemia, en donde el compuesto es un compuesto de fórmula (I):**Fórmula** en donde A es (C1-C4)-alquileno; B es -CO2H, -NH2 , -NHSO2CF3, tetrazolilo, imidazolilo, 3-hidroxiisoxazolilo, -CONHCOR'", - CONHSOR"', CONHSO2R''', donde R''' es arilo, heteroarilo, (C3 -C7)-cicloalquilo, o (C1-C4)-alquilo, opcionalmente monosustituido con (C6 -C12)-arilo, heteroarilo, OH, SH, (C1 -C4)-alquilo, (C1-C4)-alcoxi, (C1-C4)-tioalquilo, (C1- C4)-sulfinilo, (C1-C4) sulfonilo, CF3, Cl, Br, F, I, NO2, -COOH, (C2-C5)-carbonilo, NH2, mono-(C1-C4-alquil)- amino, di-(C1-C4-alquil)-amino, o (C1-C4)- perfluoroalquilo; o en donde B es un radical carboxilo CO2-G, donde G es un radical de un alcohol G-OH en el que G se selecciona de un radical (C1-C20)-alquilo, un radical (C3- C8) cicloalquilo, radical (C2-C20)-alquenilo, radical (C3-C8)-cicloalquenilo, radical retinilo, radical (C2-C20)- alquinilo, radical (C4-C20)-alqueninilo, donde los radicales alquenilo, cicloalquenilo, alquinilo, y alqueninilo contienen uno o más enlaces múltiples; radical arilo (C6-C16)-carbocíclico, radical aralquilo (C7-C16)- carbocíclico, radical heteroarilo, o radical heteroaralquilo, en donde un radical heteroaril o resto heteroarilo de un radical heteroaralquilo contiene 5 o 6 átomos en el anillo; y en donde los radicales definidos para G están sustituidos por uno o más de hidroxilo, halógeno, ciano, trifluorometilo, nitro, carboxilo, (C1-C12)-alquilo, (C3- C8)-cicloalquilo, (C5-C8)-cicloalquenilo, (C6-C12)-arilo, (C7-C16)-aralquilo, (C2-C12)-alquenilo, (C2-C12)-alquinilo, (C1-C12)-alcoxi, (C1-C12)-alcoxi-(C1-C12)alquilo, (C1-C12)-alcoxi-(C1-C12)-alcoxi, (C6-C12)-ariloxi, (C7-C16)- aralquiloxi, (C1-C8)hidroxialquilo, -O-[CH2]x-CfH(2f+1-g)-Fg, -OCF2Cl, -OCF2-CHFCl, (C1-C12)-alquilcarbonilo, (C3- C8)-cicloalquilcarbonilp, (C6-C12)-arilcarbonilo, (C7-C16)-aralquilcarbonilo, cinamoilo, (C2-C12)-alquenilcarbonilo, (C2-C12)-alquinilcarbonilo, (C1-C12)-alcoxicarbonilo, (C1-C12)-alcoxi-(C1-C12)-alcoxicarbonilo, (C6-C12)- ariloxicarbonilo, (C7-C16)-aralcoxicarbonilo, (C3-C8)-cicloalkoxicarbonilo, (C2-C12)-alqueniloxicarbonilo, (C2- C12)-alquiniloxicarbonilo, aciloxi, (C1-C12)-alcoxicarboniloxi, (C1-C12)-alcoxi-(C1-C12)-alcoxicarboniloxi, (C6-C12)- ariloxicarboniloxi, (C7-C16)-aralquiloxicarboniloxi, (C3-C8)-cicloalkoxicarboniloxi, (C2-C12)-alqueniloxicarboniloxi, (C2-C12)-alquiniloxicarboniloxi, carbamoilo, N-(C1-C12)-alquilcarbamoilo, N, N-di(C1-C12)-alquilcarbamoilo, N- (C3-C8)-cicloalquilo-carbamoilo, N-(C6-C16)-arilcarbamoilo, N-(C7-C16)-aralquilcarbamoilo, N-(C1-C10)-alquil-N- (C6-C16)-arilcarbamoilo, N-(C1-C10)-alquil-N-(C7-C16)-aralquilcarbamoilo, N-((C1-C10)-alcoxi-(C1-C10)-alquil)- carbamoilo, N-((C6-C12)-ariloxi-(C1-C10)-alquil)-carbamoilo, N-((C7-C16))-aralquiloxi-(C1-C10)-alquil)-carbamoilo, N-(C1-C10)-alquil-N-((C1-C10)-alcoxi-(C1)-C10)alquilo)-carbamoilo, N-(C1-C10)-alquil-N-((C6-C16)-ariloxi-(C1- C10)alquil)-carbamoilo, N-(C1-C10)-alquil-N-((C7-C16)-aralkiloxi-(C1-C10)alquil)-carbamoilo, carbamoiloxi, N-(C1- C12)-alquilcarbamoiloxi, N.N-di-(C1-C12)-alquilcarbamoiloxi, N-(C3-C8)-cicloalquilcarbamoiloxi, N-(C6-C12)- arilcarbamoiloxi, N-(C7-C16)-aralquilcarbamoiloxi, N-(C1-C10)-alquil-N-(C6-C12)-arilcarbamoiloxi, N(C1-C10)- alquil-N-(C7-C16)-aralquilcarbamoiloxi, N-((C1-C10)-alquil)-carbamoiloxi, N-((C6-C12)-ariloxi-(C1-C10)-alquil)- carbamoiloxi, N-((C7-C16)-aralquiloxi-(C1-C10)-alquil)-carbamoiloxi, N-(C1-C10)-alquil-N-((C1-C10)-alcoxi-(C1- C10)-alquil)-carbamoiloxi, N-(C1-C10)-alquil-N-((C6-C12)-ariloxi-(C1-C10)-alquil)-carbamoiloxi, N-(C1-C10)-alquil- N-((C7-C16)-aralquiloxi-(C1-C10)alquil)-carbamoiloxi, amino, (C1-C12)-alquilamino, di-(C1-C12)-alquilamino, (C3- C8)-cicloalquilamino, (C2-C12)-alquenilamino, (C2-C12)-alquinilamino, N-(C6-C12)-arilamino, N-(C-C11)- aralquilamino, N-alquil-aralquilamino, N-alquil-arilamino, (C1-C12)-alcoxiamino, (C1-C12)-alcoxi-N-(C1-C10)- alquilamino, (C1-C12)-alquilcarbonilamino, (C3-C8)-cicloalquilcarbonilamino, (C6-C12)-arilcarbonilamino, (C7- C16)-aralquilcarbonilamino, (C1-C12)-alquilcarbonilo-N-(C1-C10)-alquilamino, (C3-C8)-cicloalquilcarbonil-N-(Ci- Cio)-alquilamino, (C6-C12)-arilcarbonil-N-(C1-C10)alquilamino, (C7-C11)-aralquilcarbonil-N-(C1-C10)-alquilamino, (C1-C12)-alquilcarbonilamino-(C1-C8)alquilo, (C3-C8)-cicloalquilcarbonilamino-(C1-C8)alquilo, (C6-C12)- arilcarbonilamino-(C1-C8)-alquilo, (C7-C12)-aralquilcarbonilamino(C1-C8)-alquilo, amino-(C1-C10)-alquilo, N-(C1- C10) alquilamino-(C1-C10)-alquilo, N.N-di-(C1-C10)-alquilamino-(C1-C10)alquilo, (C3-C10)-cicloalquilamino-(C1- C10)-alquilo, (C1-12)-alquilmercapto, C1-C12)-alquilsulfinilo, (C1-C12)alquilsulfonilo, (C6-C16)-arilmercapto, (C6- C16)-arilsulfinilo, (C6-C12)-arilsulfonilo, (C7-C16)-aralquilmercapto, (C7-C16)-aralquilsulfinilo, (C7-C16)- aralquilsulfonilo, sulfamoilo, N-(C1-C10)-alquilsulfamoilo, N.N-di(C1-C10)-alquilsulfamoilo, (C3-C8)- cicloalquilsulfamoilo, N-(C6-C12)-alquilsulfamoilo, N-(C7-C16)-aralquilsulfamoilo, N-(C1-C10)-alquil-N-(C6-C12)- arilsulfamoilo, N-(C1-C10)-alquil-N-(C7-C16)-aralquilsulfamoilo, (C1-C10)-alquilylsulfonamido, N-((C1-C10)-alquil)- (C1-C10)-alquilsulfonamido, (C7-C16)-aralquilsulfonamido, o N-((C1-C10)-alquil-(C7-C16)-aralquilsulfonamido; en donde los radicales que son arilo o contienen un resto arilo, pueden estar sustituidos en el grupo arilo con de uno a cinco idénticos o diferentes hidroxilo, halógeno, ciano, trifluorometilo, nitro, carboxilo, (C1-C12)-alquilo, C3-C8)-cicloalquilo, (C6-C12)-arilo, (C7-C16)-aralquilo, (C1-C12)-alcoxi, (C1-C12)-alcoxi-(C1-C12)alquilo, (C1-C12)- alcoxi-(C1C12)alcoxi, (C6-C12)-ariloxi, (C7-C16)-aralquiloxi, (C1-C8)-hidroxialquilo, (C1-C12)-alquilcarbonilo, (C3- C8)-cicloalquil-carbonilo, (C6-C12)-arilcarbonilo, (C7-C16) aralquilcarbonilo, (C1-C12)-alcoxicarbonilo, (C1-C12)- alcoxi-(C1-C12)-alcoxicarbonilo, (C6-C12)-ariloxicarbonilo, (C7-C16)-aralcoxicarbonilo, (C3-C8)- cicloalcoxicarbonilo, (C2-C12)-alqueniloxicarbonilo, (C2-C12)-alquiniloxicarbonilo, (C1-C12)-alquilcarboniloxi, (C3- C8)-cicloalquilcarboniloxi, (C6-C12)-arilcarboniloxi, (C7-C16)-aralquilcarboniloxi, cinnamoiloxi, (C2-C12)- alquenilcarboniloxi, (C2-C12)-alquinilcarboniloxi, (C1-C12)-alcoxicarboniloxi, (C1-C12)-alcoxi-(C1-C12)- alcoxicarboniloxi, (C6-C12)-ariloxicarboniloxi, (C7-C16)-aralquiloxicarboniloxi, (C3-C8)-cicloalcoxicarboniloxi, (C2- C12)-alqueniloxicarboniloxi, (C2-C12)-alquiniloxicarboniloxi, carbamoilo, N-(C1-C12)-alquilcarbamoilo, N.N-di- (C1-C12)-alquilcarbamoilo, N-(C3-C8)-cicloalquilcarbamoilo, N-(C6-C12)-arilcarbamoilo, N-(C7-C16)- aralquilcarbamoilo, N-(C1-C10)-alquil-N-(C6-C12)-arilcarbamoilo, N-(C1-C10)-alquil-N-(C7-C16)- aralquilcarbamoilo, N-((C1-C10)-alcoxi-(C1-C10)-alquil)--carbamoilo, N-((C6-C12)-ariloxi-(C1-C10)-alquil)- carbamoilo, N-((C7-C16))-aralquiloxi-(Ci-Cio)-alquil)-carbamoilo, N-(Ci-Cio)-alquil-N-((Ci-Cio)-alcoxi-(Ci-Cio)- alquil)-carbamoilo, N-(C1-C10)-alquil-N-((C6-C12)-ariloxi-(C1-C10)alquilo)-carbamoil, N-(C1-C10)-alquil-N-((C7- C16)-aralquiloxi-(C1-C10)-alquil)-carbamoilo, carbamoiloxi, N-(C1-C12)-alquilcarbamoiloxi, N.N-di-(C1-C12)- alquilcarbamoiloxi, N-(C3-C8)-cicloalquilcarbamoiloxi, N-(C6-C12)-arilcarbamoiloxi, N-(C7-C16)- aralkilcarbamoiloxi, N-(C1-C10)-alquil-N-(C6-C12)-arilcarbamoiloxi, N(C1-C10)-alquil-N-(C7-C16)- aralquilcarbamoiloxi, N-((C1-C10)-alquil)-carbamoiloxi, N-((C6-C12)-ariloxi-(C1-C10)-alquil)-carbamoiloxi, N-((C7- C16)-aralquiloxi-(C1-C10)-alquil)-carbamoiloxi, N-(C1-C10)-alquil-N-((C1-C10)-alcoxi-(C1-C10)alquil)-carbamoiloxi, N-(C1-C10)-alquil-N-((C6-C12)-ariloxi-(C1-C10)alquil)-carbamoiloxi, N-(C1-C10)-alquil-N-((C7-C16)-aralkiloxi-(C1- C10)alquilo)-carbamoiloxi, amino, (C1-C12)-alquilamino, di-(C1-C12)-alquilamino, (C3-C8)-cicloalquilamino, (C3- C12)-alquenilamino, (C3-C12)-alquinilamino, N-(C6-C12)-arilamino, N-(C7-C11)-aralquilamino, Nalquilaralquilamino, N-alquil-arilamino, (C1-C12)-alcoxiamino, (C1-C12)-alcoxi-N-(C1-C10)alquilamino, (C1-C12)- alquilcarbonilamino, (C3-C8)-cicloalquilcarbonilamino, (C6-C12)-arilcarbonilamino, (C7-C16)-alquilcarbonilamino, (C1-C12)-alquilcarbonil-N-(Ci-Cio)-alquilamino, (C3-C8)-cicloalquilcarbonil-N-(C1-C10)-amino, (C6-C12)- arilcarbonil-N-(C1-C10)-alquilamino, (C7-C11)-aralquilcarbonil-N-(C1-C10)-alquilamino, (C1-C12)- alquilcarbonilamino-(C1-C8)-alquilo, (C3-C8))-cicloalquilcarbonilamino-(C1-C8)-alquilo, (C6-C12)- arilcarbonilamino-(C1-C8)-alquilo, (C7-C16)-aralquilcarbonilamino-(C1-C8)-alquilo, amino-(Ci-C10)alquilo, N-(C1- C10)alquilamino-(C1-C10)alquilo, N.N-di-(C1-C10)-alquilamino-(C1-C10)alquilo, (C3-C8)-cicloalquilamino-(C1-C10)- alquilo, (C1-C12)-alquilmercapto, (C1-C12)-alquilsulfinilo, (C1-C12)alquilsulfonilo, (C6-C12)-arilmercapto, (C6-C12)- arilsulfinilo, (C6-C12)-arilsulfonilo, (C7-C16)-aralquilmercapto, (C7-C16)-aralquilsulfinilo, o (C7-C16)- aralquilsulfonilo; X es O o S; Q es O, S, NR', o un enlace; donde, si Q es un enlace, R4 es halógeno, nitrilo, o trifluorometilo; o donde, si Q es O, S, o NR', R4 es hidrógeno, racial (C1-C10)-alquilo, radical (C2-C10)-alquenilo, radical (C2- C10)-alquinilo, en donde el radical alquenilo o alquinilo contiene uno o dos enlaces múltiples C-C; radical fluoroalquilo no sustituido de la fórmula -[CH2]x-CfH(2f+1-g)-Fg, radical (C1-C8)-alcoxi-(C1-C6)-alquilo, radical (C1- C6)-alcoxi-(C1-C4)-alcoxi-(C1-C4)-alquilo, radical arilo, radical heteroarilo, radical (C7-C11)-aralquilo, o un radical de la fórmula Z -[CH2]v-[O]w-[CH2]t-E(Z)

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式